|Mr. Jonathan P. Mow||Pres, CEO & Director||678.78k||N/A||1965|
|Mr. John P. Sharp||Chief Financial Officer||548.51k||N/A||1965|
|Dr. John S. Lee||Chief Medical Officer||581.5k||N/A||1968|
|Mr. Kristopher L. Hanson||VP, Head of Legal & Corp. Sec.||N/A||N/A||1972|
|Mr. Michael B. York||VP of Corp. Devel. & Commercial Strategy||N/A||N/A||1965|
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.